Novel therapies in the treatment of spondyloarthritis

Expert Opinion on Investigational Drugs

Volumn 11, Issue 7, 2002, Pages 937-946

  Maksymowych, Walter P ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Ankylosing spondylitis; Bisphosphonates; Etanercept; Infliximab; Psoriatic arthritis; Spondyloarthritis

Indexed keywords

ALEFACEPT; ANTIMALARIAL AGENT; AURANOFIN; AZATHIOPRINE; AZITHROMYCIN; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CIPROFLOXACIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GOLD; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEFLUNOMIDE; LYMECYCLINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PENICILLAMINE; PLACEBO; SALAZOSULFAPYRIDINE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DELAYED HYPERSENSITIVITY; DROWSINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; DRUG TOLERABILITY; FEVER; HUMAN; LYMPHOMA; MOUSE; MYALGIA; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PERIPHERAL NEUROPATHY; PSORIATIC ARTHRITIS; RAT; REVIEW; STANDARDIZATION; SYMPTOMATOLOGY; TUBERCULOSIS; VERTIGO; ANIMAL; DRUG EFFECT; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; T LYMPHOCYTE;

ANIMAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DIPHOSPHONATES; HUMAN; IMMUNOGLOBULIN G; MODELS, ANIMAL; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR; ANIMALS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035986899     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.7.937     Document Type: Review

References (54)

1. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: Influence of disease duration and activity
2. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis
3. Preliminary core sets for endpoints in ankylosing spondylitis
4. Functional disability predicts total costs in patients with ankylosing spondylitis
5. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index
6. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis
7. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondyloarthropathy
8. Immunohistological study of entheses in spondyloathropathies: Comparison in rheumatoid arthritis and osteoarthritis
9. Recurrence risk modeling of the genetic susceptibility to ankylosing spondylitis
10. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: An animal model of HLA-B27-associated human disorders
11. Gut inflammation in the spondyloarthropathies: Clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study
12. Arthritis induced by proteoglycan aggrecan G1 domain in BALB/c mice. Evidence for T cell involvement and the immunosuppressive influence of keratan sulfate on recognition of T and B cell epitopes
13. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
14. Ankylosing spondylitis: What is the optimum duration of a clinical study? One year versus a 6 weeks nonsteroidal anti-inflammatory drug trial
15. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: A six-week controlled study with comparison against placebo and against a conventional nonsteroidal anti-inflammatory drug
16. Sulfasalazine in the treatment of spondyloarthropathy
17. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis
18. The Bath Ankylosing Spondylitis Radiology Index (BASRI)
19. Stoke ankylosing spondylitis score
20. Benign and malignant musculoskeletal lesions: Dynamic contrastenhanced MR imaging - Parametric 'first-pass' images depict tissue vascularization and perfusion
21. Low T cell production of TNFα and IFNγ in ankylosing spondylitis: Its relation to HLA-B27 and influence of the TNF -308 gene polymorphism
22. Transgenic mice expressing a truncated Peromyscus leucopus TNF-α gene manifest an arthritis resembling ankylosing spondylitis
23. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: An open pilot study
24. TNFα blockade with infliximab in patients with active spondyloarthropathy: Follow up of one year maintenance regime
25. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα
26. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondyloarthropathy: Histologic findings in eight patients from an open-label pilot study
27. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy
28. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab
29. Infliximab treatment of severe ankylosing spondylitis: One-year followup
30. Treatment of active ankylosing spondylitis with infliximab: A randomized controlled multicentre trial
31. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis
32. Efficacy of infliximab in severe refractory ankylosing spondylitis (AS) results of a 6 month follow-up open-label study
33. Infliximab in ankylosing spondylitis: A prospective observational inception cohort analysis of efficacy and safety
34. Successful treatment of psoriatic arthritis with infliximab in an MRI-controlled study
35. Successful sshort term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-α monoclonal antibody infliximab
36. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial
37. Etanercept in patients with psoriatic arthritis and psoriasis
38. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept: Results of a Phase III multicentre clinical trial
39. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α
40. An open label trial of etanercept in the treatment of ankylosing spondylitis
41. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondyloarthropathy
42. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis
43. The efficacy of thalidomide in severe refractory seronegative spondyloarthropathy: Reply to Lee et al
44. Therapeutic effect and molecular targets of thalidomide in refractory ankylosing spondylitis
45. Leflunomide for psoriatic arthritis and psoriasis
46. Alefacept (LFA3-IgG1 fusion protein) reduces synovial inflammatory infiltrate and improves outcome in psoriatic arthritis
47. Studies on the chronic phase of adjuvant arthritis: Effect of SR 41319, a new diphosphonate
48. NE-58095: A diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis
49. Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNF∝ secretion from RAW 264 cells in vitro
50. Inhibition of antigen-presenting cell function by alendronate in vitro
51. Significant loss of bone mass in patients with early, active ankylosing spondylitis. A follow up study
52. An open study of pamidronate in the treatment of refractory ankylosing spondylitis
53. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy
54. A six-month randomized, controlled, double-blinded, dose response comparison of intravenous pamidronate (60mg versus 10 mg) in the treatment of NSAID-refractory ankylosing spondylitis